<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923867</url>
  </required_header>
  <id_info>
    <org_study_id>C-DGSUT-001</org_study_id>
    <nct_id>NCT04923867</nct_id>
  </id_info>
  <brief_title>The Primary Objective of the Study is to Retrospectively Evaluate the Safety and Efficacy of the Suturable DuraGen™</brief_title>
  <official_title>A Multicenter, Retrospective, Post-Market Clinical Follow-Up Study to Evaluate the Performance and Safety of Suturable DuraGen™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integra LifeSciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to retrospectively collect data on the safety and efficacy&#xD;
      of Suturable DuraGen™.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, non-randomized, non-interventional, retrospective Post-Market Clinical&#xD;
      Follow-up (PMCF) study to evaluate the occurrence of post-operative cerebrospinal fluid (CSF)&#xD;
      leaks within 30 days (and up to 90 days) after use of Suturable DuraGen™ for a&#xD;
      supratentorial, infratentorial, or spinal procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Outcome</measure>
    <time_frame>post-up to 90 days</time_frame>
    <description>Occurrence of post-operative cerebrospinal fluid (CSF) leaks post-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Event</measure>
    <time_frame>Between days 30-90</time_frame>
    <description>Adverse event that occurred between days 30-90 post-operatively</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Cerebrospinal Fluid Leak</condition>
  <arm_group>
    <arm_group_label>Supratentorial Procedure Group</arm_group_label>
    <description>Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infratentorial Procedure Group</arm_group_label>
    <description>Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinal Procedure Group</arm_group_label>
    <description>Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suturable DuraGen™</intervention_name>
    <description>Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.</description>
    <arm_group_label>Infratentorial Procedure Group</arm_group_label>
    <arm_group_label>Spinal Procedure Group</arm_group_label>
    <arm_group_label>Supratentorial Procedure Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neurosurgery service in Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is between 18 and 80 years of age&#xD;
&#xD;
          2. Subject has undergone either a supratentorial, an infratentorial, or a spinal&#xD;
             procedure with the use of Suturable DuraGen™ prior to trial initiation&#xD;
&#xD;
          3. Availability of post-operative assessment results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. There are no exclusionary criteria for this study population&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Tummon</last_name>
    <role>Study Director</role>
    <affiliation>Integra LifeSciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samira Lavingia</last_name>
    <phone>732-647-5017</phone>
    <email>samira.lavingia@integralife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ormond, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Bell</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Shaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Yau</last_name>
    </contact>
    <investigator>
      <last_name>Justin Cetas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrospinal Fluid Leak</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

